Arcellx (ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for anito-cel in ...

Based on the latest available data, ACLX has gained about 78.7% so far this year. Meanwhile, the Medical sector has returned an average of 4% on a year-to-date basis. This means that Arcellx, Inc. is ...

Piper Sandler raised the firm’s price target on Arcellx (ACLX) to $115 from $91 and keeps an Overweight rating on the shares following Q3 ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating on November 6. Tyler Van Buren has ...

Arcellx (NASDAQ:ACLX – Get Free Report) had its price target increased by Morgan Stanley from $81.00 to $106.00 in a research ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

Arcellx, Inc. (ACLX) shares rallied 6.7% in the last trading session to close at $92.98. This move can be attributable to ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

During the last three months, 7 analysts shared their evaluations of Arcellx ACLX +4.99% Get Free Report , revealing diverse ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

On Tuesday, Arcellx Inc (ACLX) stock saw a modest uptick, ending the day at $87.12 which represents a slight increase of $0.68 or 0.79% from the prior close of $86.44. The stock opened at $80.22 and ...

Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its therapy candidate anito-cel for the treatment of multiple myeloma.